Roche obesity drug shows blood sugar control and 15.5% weight loss
Roche said its experimental dual-acting obesity drug improved blood sugar control and drove an average 15.5% body-weight loss in a mid-stage trial in overweight or obese patients with type 2 diabetes.
Swiss drugmaker Roche BX:RHO said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial. Roche is competing with large drugmakers, including AstraZe…